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phages after LPS and IL-4 stimulation,
respectively, were identical in WT and
Arg1 macrophages. Therefore, the au-
thors conclude that “arginase-1-indepen-
dent polyamine production stimulates
the expression of alternatively activated
macrophage markers”. This point puts
into question the use of Arg1 as a
marker of alternatively activated macro-
phages. The authors imply that there is
a mechanism whereby polyamine syn-
thesis occurs through a metabolic path-
way that does not involve arginase activ-
ity, but this theoretical pathway remains
to be elucidated. Regardless of which
pathway(s) may be used by macro-
phages for polyamine biosynthesis, the
data in this manuscript demonstrate
that endogenous polyamines play a ma-
jor function in regulation of macro-
phage activation.
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Emerging data demonstrate thatHDACi, initially developed asanticancer agents, are also po-
tent anti-inflammatory agents at non-
cytotoxic doses [1, 2]. The mecha-
nisms and promise of HDACi-medi-
ated immune modulation are
increasingly understood [1]. In this
issue, Rosborough and colleagues [3]
report a novel role for HDACi in regu-
lating immune responses (Fig. 1).
They demonstrate that HDACi en-
hance the generation and expansion
of MDSCs, a key subset of regulatory
APCs [4].
HDACs remove acetyl groups from
-N-acetyl lysine amino acids on his-
tone tails and regulate chromatin
structure and dynamics [5–7]. Emerg-
ing data also show that in addition to
regulating acetylation of lysines within
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histones, HDAC enzymes regulate the
acetylation of several nonhistone pro-
teins [8 –11]. They are classified into
four main classes: class I HDACs in-
clude HDAC1, -2, -3, and -8; class II
HDACs are HDAC4, -5, -7, and -9
(class IIa) and HDAC6 and -10 (class
IIb); class III HDACs are homologs of
yeast silent information regulator 2
proteins; and class IV HDAC is
HDAC11 [11]. Class I HDAC enzymes
are expressed in most cells and are
largely, but not exclusively, restricted
to the nucleus. By contrast, class II
HDAC enzymes demonstrate a more
restricted, tissue-specific expression
and shuttle between the nucleus and
cytoplasm [7, 12]. Most HDACi inhibit
class I and II enzymes with varying ef-
ficiency [11]. The catalytic activities of
the class I and II HDACs differ [7].
Class I HDAC enzymes exhibit strong
deacetylase activity, whereas most class
II HDACs are enzymatically less active
and act primarily as scaffolding pro-
teins within large multimolecular com-
plexes.
HDACi belong to different classes of
drugs with distinct chemical structures
and abilities to inhibit HDAC enzymes
[11, 13–15]. The two HDACi, used by
Rosborough et al. [3]—TSA and
SAHA—are nonselective, pan-HDACi
that inhibit class I and II [11, 16].
HDACi can also modulate the acetyla-
tion of HDAC proteins themselves,
causing alterations in their stability or
activity [7]. They have been shown to
regulate the function of various im-
mune cells and modulate in vivo dis-
ease states in experimental models [1,
17]. Specifically, their impact on Tregs
and T cell responses is being appreci-
ated increasingly [13, 18]. Recent data
have demonstrated the ability of these
agents to inhibit the production of
multiple proinflammatory cytokines
from various APCs [1]. HDAC inhibi-
tion has been shown to enhance IDO
expression in DCs, promote conver-
sion of inflammatory macrophages
into a tolerogenic phenotype, decrease
TLR signaling, reduce costimulatory
molecule expression, and increase
IL-10 expression [19 –22]. But, the
mechanisms of action of HDACi on
different APC subsets and their gener-
ation and function are not understood
completely.
MDSCs are now being appreciated in-
creasingly as key APC subsets that are re-
sponsible for regulating immune re-
sponses. They potently suppress T effector
cell responses while enhancing Tregs
[23]. They are a heterogeneous popula-
tion of immature myeloid cells that con-
sists of myeloid progenitors and precur-
sors [4]. MDSCs are identified in murine
studies as cells that are positive for CD11b
and Gr-1. Based on expression of Ly-6C
or Ly-6G, they can be characterized fur-
ther as monocytic MDSCs (CD11b Ly-
6G Ly-6Chigh) or granulocytic MDSCs
(CD11b Ly-6G Ly-6Clow) [23]. The
mechanisms of suppression of T cell re-
sponses by MDSCs include a high level of
arginase activity, NO, ROS production,
induction of Tregs, secretion of TGF-,
depletion of cysteine, and up-regulation
of PGE2. The distinct subsets of MDSCs
use differential pathways for regulating
immune responses [4, 22, 23]. For exam-
ple, granulocytic MDSCs are reported to
be dependent on ROS, whereas mono-
cytic MDSCs are more dependent on argi-
nase and NO for regulating T cell re-
sponses [4].
The powerful immune-suppressive
features of MDSC make them attrac-
tive candidates for use in cell therapy
to reduce unwanted and exuberant
immune responses, such as in autoim-
munity, graft rejection, and GVHD
[23, 24]. To facilitate such studies, it
would be essential to generate, ex
vivo, relatively large and stable im-
mune-suppressive MDSCs. Murine
studies have demonstrated that G-CSF
expands MDSCs in vitro and in vivo
[23]. Rosborough et al. [3] analyzed
the impact of HDAC inhibition on the
generation and function of MDSCs.
They demonstrate that HDAC inhibi-
tion of BM GM-CSF-treated cultures
with TSA or SAHA expanded the HSC
and progenitor compartments, skewed
myeloid differentiation, impaired the
development of DCs, and enhanced
the generation of MDSCs. Although
addition of rIL-4 to the cultures ex-
panded the progenitor cells and dem-
onstrated skewed myeloid differentia-
tion, it did not enhance the genera-
tion of MDSCs. Upon further
characterization, they found that these
MDSCs expressed CD11b F4/80int
and Ly-6Chigh, suggesting generation
of a monocytic MDSC phenotype.
These cells demonstrated equivalent
suppression of allogeneic T cell re-
sponses in vitro. However, in contrast
to control MDSCs, those derived fol-
lowing HDAC inhibition showed re-
duced expression of arginase, iNOS,
and HO-1. Furthermore, arginase was
not required, whereas iNOS and HO-1
activity was required for the suppres-
sive effects on allogeneic T cells. Im-
portantly, HDAC inhibition also aug-
mented in vivo expansion of MDSCs
in BM and spleen by GM-CSF, al-
SUMMARY:
• HDAC inhibition regulates innate responses and DC functions
• Inhibition of HDAC enzymes in GMCSF treated BM progenitors impairs DC but promotes
     MDSC differentiation
• The MDSCs generated by HDAC inhibition demonstrate the expected in vitro suppressive 
     functions that are dependent on iNOS and HO-1 
• HDAC inhibition augments MDSCs numbers in vivo 
IMPLICATIONS:
• Insight into HDAC inhibition mediated immune regulation
• Provide a platform for ex vivo expansion of MDSCs that may be exploited therapeutically
• The stability, phenotype and functional relevance of the in vivo expansion of MDSCs remain 
     to be analyzed
• The specific HDACs and HATs involved in MDSC differentiation need to be determined
• The critical epigenetic and the non-histone proteins that must be acetylated need to be understood
Figure 1. Summary and implications.
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though the functional impact of this
in vivo expansion was not addressed.
This study, like all interesting and
seminal observations, while illuminat-
ing a role for HDAC inhibition in the
generation of MDSCs, also raises sev-
eral additional questions. Why did the
addition of IL-4 prevent the increase
in MDSC generation despite the in-
crease in HSC and progenitors? Is the
increase in HSCs and progenitors criti-
cal and relevant? Or is it merely an
epiphenomenon? The developmental
pathways that are critical for MDSC
generation remain largely unknown,
and how would those pathways af-
fected by HDAC inhibition remain to
be deciphered? What would be the
impact on the phenotype of
MDSCs, especially in vivo? Is that func-
tionally relevant? An intriguing obser-
vation is that the differential mecha-
nisms that might be used by the
HDACi induced MDSCs. The role of
arginase, iNOS, and HO-1, in addition
to the other pathways, such as induc-
tion of Tregs, relevance of cysteine
depletion, and PGE2, remains to be
understood as well [23, 25–27]. Fur-
thermore, the key molecular mecha-
nisms remain to be explored. In addi-
tion to histone deacetylation and epi-
genetic alterations, is acetylation of
nonhistone proteins critical? Further
identification of the specific HDAC
enzyme, the specific histone acetyl-
transferase, and their putative targets
in generating MDSCs will refine our
understanding of the role of protein
acetylation and MDSC biology.
This study expands the scope of
HDAC inhibition-mediated immune
regulation and provides a novel
method for generating MDSCs with
greater efficiency, both in vitro and in
vivo. It provides texture to our current
understanding of the role of HDAC
inhibition in regulating immune re-
sponses. Importantly, in light of the
known immune-regulatory effects of
MDSCs, the observations by Rosbor-
ough and colleagues [3] may pave way
for building a platform to robustly ex-
pand MDSCs ex vivo and thus, facili-
tate well-designed, adoptive cell-ther-
apy trials to study the potential of
MDSCs in regulating autoimmunity,
allograft rejection, and GVHD.
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